The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
News|Articles|July 2, 2026
Breast Cancer News Roundup: June 2026
Author(s)Targeted Oncology Staff
Fact checked by: Sabrina Serani
ASCO 2026 highlights, FDA moves, and AI mammography sharpen breast cancer care—ADCs, ctDNA, and de-escalation reshape treatment and screening debates.
Advertisement
Advertisement
June was a dense month for breast cancer research and regulation, anchored by the ASCO 2026 Annual Meeting, three new FDA actions, and fresh debate over screening guidelines and AI-driven detection. Here's a rundown of what mattered.
Related to this article
More than 76% of US counties have no TNBC trial, and only 9.8% of rural counties have one vs 47% of metropolitan counties, a new analysis finds.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Advertisement
Advertisement